section name header

Evidence summaries

Metal Protein Attenuating Compounds for Alzheimer's Disease

There is no evidence that clioquinol (PBT1) would provide any clinical benefit for patients with Alzheimer's disease. Level of evidence: "D"

A Cochrane review [Abstract] 1 included one study with a total of 36 subjects. Clioquinol (PBT1) was compared with placebo. There was no statistically significant difference in cognition (as measured on the ADAS-Cog scale) between active treatment and placebo groups at 36 weeks. One subject in the active treatment group developed neurological symptoms (impaired visual acuity and colour vision) which resolved on cessation of treatment and was thought to be possibly attributable to the drug.

Comment: The quality of evidence is downgraded by limitations in study quality (inadequate or unclear allocation concealment), by imprecise results (few patients) and by indirectness (differences in studied patients).

    References

    • Sampson E, Jenagaratnam L, McShane R. Metal protein attenuating compounds for the treatment of Alzheimer's disease. Cochrane Database Syst Rev 2008 Jan 23;(1):CD005380. [PubMed]

Primary/Secondary Keywords